GSK’s Promacta And Amgen’s Nplate Face Off In ITP Market
Executive Summary
GlaxoSmithKline/Ligand's Promacta (eltrombopag) received FDA approval Nov. 20 as a second-line treatment of thrombocytopenia in patients with the rare blood disorder chronic idiopathic thrombocytopenic purpura. The approval was widely anticipated, although it came five months after the drug's original PDUFA date